| 1 | al 18 june 2024 | | | | | | | 3 | 0.65% |
| 2 | 34 no 1 2024 | | | | | | | 3 | 0.65% |
| 3 | et al 18 june | | | | | | | 3 | 0.65% |
| 4 | vol 34 no 1 | | | | | | | 3 | 0.65% |
| 5 | the study of headaches | | | | | | | 2 | 0.43% |
| 6 | journal of the italian | | | | | | | 2 | 0.43% |
| 7 | society for the study | | | | | | | 2 | 0.43% |
| 8 | for the study of | | | | | | | 2 | 0.43% |
| 9 | june 2024 vol 34 | | | | | | | 2 | 0.43% |
| 10 | 18 june 2024 vol | | | | | | | 2 | 0.43% |
| 11 | scopus openalex analytics most | | | | | | | 1 | 0.22% |
| 12 | to review indexing indexing | | | | | | | 1 | 0.22% |
| 13 | how to review indexing | | | | | | | 1 | 0.22% |
| 14 | skip to main content | | | | | | | 1 | 0.22% |
| 15 | reviewers how to review | | | | | | | 1 | 0.22% |
| 16 | analytics most read last | | | | | | | 1 | 0.22% |
| 17 | for reviewers how to | | | | | | | 1 | 0.22% |
| 18 | benefits for reviewers how | | | | | | | 1 | 0.22% |
| 19 | reviewers benefits for reviewers | | | | | | | 1 | 0.22% |
| 20 | review article reviewers for | | | | | | | 1 | 0.22% |
| 21 | a review article reviewers | | | | | | | 1 | 0.22% |
| 22 | write a review article | | | | | | | 1 | 0.22% |
| 23 | to write a review | | | | | | | 1 | 0.22% |
| 24 | paper how to write | | | | | | | 1 | 0.22% |
| 25 | scientific paper how to | | | | | | | 1 | 0.22% |
| 26 | a scientific paper how | | | | | | | 1 | 0.22% |
| 27 | openalex analytics most read | | | | | | | 1 | 0.22% |
| 28 | last month confinia cephalalgica | | | | | | | 1 | 0.22% |
| 29 | most read last month | | | | | | | 1 | 0.22% |
| 30 | cortical excitability in patients | | | | | | | 1 | 0.22% |
| 31 | visual evoked potentials study | | | | | | | 1 | 0.22% |
| 32 | a visual evoked potentials | | | | | | | 1 | 0.22% |
| 33 | symptoms a visual evoked | | | | | | | 1 | 0.22% |
| 34 | depressive symptoms a visual | | | | | | | 1 | 0.22% |
| 35 | and depressive symptoms a | | | | | | | 1 | 0.22% |
| 36 | aura and depressive symptoms | | | | | | | 1 | 0.22% |
| 37 | patients with migraine with | | | | | | | 1 | 0.22% |
| 38 | in patients with migraine | | | | | | | 1 | 0.22% |
| 39 | excitability in patients with | | | | | | | 1 | 0.22% |
| 40 | 340 cortical excitability in | | | | | | | 1 | 0.22% |